Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 20, 2021 - Issue 11
Submit an article Journal homepage
445
Views
6
CrossRef citations to date
0
Altmetric
Original research

Serious adverse events with tedizolid and linezolid: pharmacovigilance insights through the FDA adverse event reporting system

Milo Gattia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy;b SSD Clinical Pharmacology, IRCSS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3018-3779View further author information
ORCID Icon,
Michele Fusarolia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, ItalyView further author information
,
Emanuel Raschia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0003-0487-7996View further author information
ORCID Icon,
Ugo Morettic Department of Public Health and Community Medicine, University of Verona, Verona, ItalyView further author information
,
Elisabetta Poluzzia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-7209-0426View further author information
ORCID Icon &
Fabrizio De Pontia Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, ItalyORCID Iconhttps://orcid.org/0000-0002-0367-9595View further author information
ORCID Icon
Pages 1421-1431 | Received 28 Mar 2021, Accepted 13 Jul 2021, Published online: 19 Jul 2021

References

  • Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013 Feb 13;309(6):559–569.
  • Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014 Aug;14(8):696–705.
  • Roger C, Roberts JA, Muller L. Clinical pharmacokinetics and pharmacodynamics of oxazolidinones. Clin Pharmacokinet. 2018 May;57(5):559–575.
  • Lodise TP, Fang E, Minassian SL, et al. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Antimicrob Agents Chemother. 2014 Dec;58(12):7198–7204.
  • Lan SH, Lin WT, Chang SP, et al. Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-Analysis. Antibiotics (Basel). 2019 Sep 4;8(3):137.
  • Mensa Vendrell M, Tasias Pitarch M, Salavert Lletí M, et al. Safety and tolerability of more than six days of tedizolid treatment. Antimicrob Agents Chemother. 2020Jun23;64(7):e00356–20.
  • Lee EY, Caffrey AR. Thrombocytopenia with tedizolid and linezolid. Antimicrob Agents Chemother. 2017 Dec 21; 62(1):e01453–17.
  • European Medicines Agency. Designated Medical Event (DME) list. 2020. Accessed 2020 Aug 22. https://www.ema.europa.eu/en/documents/other/designated-medical-event-dme-list_en.xlsx
  • Raschi E, Poluzzi E, Salvo F, et al., Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 28(6): 533–542. 2018.
  • Edwards JR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet. 2000;356(9237):1255e9.
  • Flanagan S, McKee EE, Das D, et al. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function. Antimicrob Agents Chemother. 2015 Jan;59(1):178–185.
  • Milosevic TV, Payen VL, Sonveaux P, et al. Mitochondrial alterations (inhibition of mitochondrial protein expression, oxidative metabolism, and ultrastructure) induced by linezolid and tedizolid at clinically relevant concentrations in cultured human HL-60 promyelocytes and THP-1 monocytes. Antimicrob Agents Chemother. 2018 Feb 23;62(3):e01599–17.
  • Srivastava S, Deshpande D, Nuermberger E, et al. The sterilizing effect of intermittent tedizolid for pulmonary tuberculosis. Clin Infect Dis. 2018 Nov 28;67(suppl_3):S336–S341.
  • Giménez-Arufe V, Gutiérrez-Urbón JM, Blanco-Aparicio M, et al. Pulmonary nocardiosis treated with tedizolid. Farm Hosp. 2019 Nov 1;43(6):208–210.
  • Khatchatourian L, Le Bourgeois A, Asseray N, et al. Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments. J Antimicrob Chemother. 2017Jul1;72(7):2135–2136.
  • David MZ, Daum RS. Treatment of staphylococcus aureus infections. Curr Top Microbiol Immunol. 2017;409:325–383.
  • Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006 Jun 1;42(11):1578–1583.
  • Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2020 Sep 8. Online ahead of print. doi: https://doi.org/10.1007/s00228-020-02990-1
  • Cojutti PG, Merelli M, Bassetti M, et al. Proactive therapeutic drug monitoring (TDM) may be helpful in managing long-term treatment with linezolid safely: findings from a monocentric, prospective, open-label, interventional study. J Antimicrob Chemother. 2019 Dec 1;74(12):3588–3595.
  • Cheng CN, Wu CC, Kuo CH, et al. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions. J Formos Med Assoc. 2021 Jan;120(1 Pt 2):466-475. doi:https://doi.org/10.1016/j.jfma.2020.06.011.
  • Crass RL, Cojutti PG, Pai MP, et al. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00605–19.
  • European Medicine Agency. Sivextro: EPAR – risk-management-plan summary. [ cited 17 December 2020]. https://www.ema.europa.eu/en/documents/rmp-summary/sivextro-epar-risk-management-plan-summary_en-0.pdf

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.